drugset / Trial / NCT05002946

Pharmacokinetics of SP-104

NCT05002946

Phase 1 Completed 18 enrolled Scilex Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

This open-label, 3-period, 3-treatment, randomized study will characterize the pharmacokinetics and safety and tolerability of SP-104 under fasting and fed conditions as compared to the pharmacokinetics of Naltrexone Hydrochloride Tablets, USP, 50 mg in healthy adult subjects.

Timeline

Start
2022-01-11
Primary completion
2022-04-24
Completion
2022-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified Oral
Comparator Naltrexone Small molecule 50 mg Oral

Indications

No indication recorded.